Skip to main content
Caplight Logo









ProNeurogen, Inc.

ProNeurogen, Inc.

Private
Tucson, ArizonaHealthcare & Life Scienceshttps://www.proneurogen.com/

Last Round

Grant

Nov 15, 2023

Total Funding Raised

$1.94M

Company Overview

ProNeurogen, Inc. is a biotechnology company that develops novel peptide-based therapeutics to treat vascular dementia, cognitive impairment, and inflammation-related brain disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalpeptide therapeuticsneuroinflammationdrug discoveryvascular dementiacognitive impairmentbiotech startupclinical-stageblood-brain barrierneurodegenerative diseasedrug developmentMas receptorsmall molecule drugbiotech licensingNIH funding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ProNeurogen, Inc. Comparables

Compare ProNeurogen, Inc. with similar companies based on industry and business-model similarity.

ProNeurogen, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Constant Therapeutics
80%
NeuroTherapia, Inc.
78%
Longevity Biotech
78%

ProNeurogen, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 15, 2023
GrantSep 18, 2023
GrantSep 16, 2020

Key People

Founding team and executive leadership

Meredith Hay

CEO, Founder and Director

Founding Team

ProNeurogen, Inc. Investors

Notable investors and investment history

ProNeurogen, Inc. investors
InvestorRounds
National Institute on AgingGrant
National Institutes of Health (NIH)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors grew 84% MoM, from 113 to 208.

  • Jan 26, 2025

    Monthly visitors grew 31% MoM.

ProNeurogen, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ProNeurogen, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ProNeurogen, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTucson, Arizona
Employee Range4
Year Founded2013
Last FundingNov 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?